 |
Top 18 Cystic fibrosis treatment startups
Oct 10, 2024 | By Jason Kwon | 19 |
These startups develop new diagnostics and treatment technologies for Cystic fibrosis, like genome analyses, lung function monitoring devices, wearable biosensors, gene therapy, new drugs...
1
Country: USA | Funding: $510.5M
Morphic Therapeutic is developing oral, small-molecule formulations aimed at the family of common cell-surface receptors linked to inflammation, fibrosis, oncology and cardiometabolic disease.
Morphic Therapeutic is developing oral, small-molecule formulations aimed at the family of common cell-surface receptors linked to inflammation, fibrosis, oncology and cardiometabolic disease.
2
Country: USA | Funding: $442.6M
Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
3
Country: USA | Funding: $292M
Sionna’s batch of small molecules will be the first to fully restore function to the cystic fibrosis transmembrane conductance regulator (CFTR) protein
Sionna’s batch of small molecules will be the first to fully restore function to the cystic fibrosis transmembrane conductance regulator (CFTR) protein
4
Country: France | Funding: $179.8M
Inventiva is a clinical stage biopharmaceutical company with an expertise in fibrosis, oncology and orphan diseases. We are focussing on diseases with a high unmet medical need where either no treatments are available, such as NASH and Systemic Sclerosis, or the current standard of care leaves important manifestations of the diseases unaffected, as it is the case in many lysosomal storage diseases.
Inventiva is a clinical stage biopharmaceutical company with an expertise in fibrosis, oncology and orphan diseases. We are focussing on diseases with a high unmet medical need where either no treatments are available, such as NASH and Systemic Sclerosis, or the current standard of care leaves important manifestations of the diseases unaffected, as it is the case in many lysosomal storage diseases.
5
Country: Denmark | Funding: $160.4M
Galecto develops galectin modulators for the treatment of severe diseases, including fibrosis and cancer. The company builds on more than 10 years of research into galectins and galectin modulators, which combined with a strong patent estate gives Galecto Biotech a unique platform.
Galecto develops galectin modulators for the treatment of severe diseases, including fibrosis and cancer. The company builds on more than 10 years of research into galectins and galectin modulators, which combined with a strong patent estate gives Galecto Biotech a unique platform.
6
Country: USA | Funding: $145.6M
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
7
Country: UK | Funding: £68.8M
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
8
Country: USA | Funding: $63M
Stablix Therapeutics, a biotechnology company pioneering the Targeted Protein Stabilization technologies that is used to cure cystic fibrosis and cancer
Stablix Therapeutics, a biotechnology company pioneering the Targeted Protein Stabilization technologies that is used to cure cystic fibrosis and cancer
9
Country: USA | Funding: $60M
Kojin Therapeutics is developing transformative medicines based on a groundbreaking approach to ferroptosis and cell state biology. Our approach opens new avenues for the treatment of cancer, fibrosis, ischemia, and immune modulation.
Kojin Therapeutics is developing transformative medicines based on a groundbreaking approach to ferroptosis and cell state biology. Our approach opens new avenues for the treatment of cancer, fibrosis, ischemia, and immune modulation.
10
Country: USA | Funding: $53.9M
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions. Our therapies for Idiopathic Pulmonary Fibrosis and Loculated Pleural Effusion bring hope to patients whose only treatment options may be invasive surgery or costly and ineffective drugs. We aim to create better pharmaceutical treatment options for IPF, LPE, and other underserved lung conditions.
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions. Our therapies for Idiopathic Pulmonary Fibrosis and Loculated Pleural Effusion bring hope to patients whose only treatment options may be invasive surgery or costly and ineffective drugs. We aim to create better pharmaceutical treatment options for IPF, LPE, and other underserved lung conditions.
